Compare Piramal Healthcare with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs STRIDES PHARMA SCIENCE - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES STRIDES PHARMA SCIENCE PIRAMAL ENTERPRISES/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x -31.2 19.2 - View Chart
P/BV x 1.1 1.8 59.5% View Chart
Dividend Yield % 2.2 0.3 801.9%  

Financials

 PIRAMAL ENTERPRISES   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
PIRAMAL ENTERPRISES/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3,3031,147 287.9%   
Low Rs1,797642 279.9%   
Sales per share (Unadj.) Rs716.5317.2 225.8%  
Earnings per share (Unadj.) Rs79.77.8 1,016.0%  
Cash flow per share (Unadj.) Rs107.925.1 430.6%  
Dividends per share (Unadj.) Rs28.002.00 1,400.0%  
Dividend yield (eoy) %1.10.2 491.2%  
Book value per share (Unadj.) Rs1,477.5274.3 538.7%  
Shares outstanding (eoy) m184.4589.50 206.1%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x3.62.8 126.2%   
Avg P/E ratio x32.0114.0 28.1%  
P/CF ratio (eoy) x23.635.7 66.2%  
Price / Book Value ratio x1.73.3 52.9%  
Dividend payout %35.125.5 137.8%   
Avg Mkt Cap Rs m470,29280,058 587.4%   
No. of employees `0007.82.5 311.9%   
Total wages/salary Rs m22,5044,341 518.5%   
Avg. sales/employee Rs Th16,899.411,325.8 149.2%   
Avg. wages/employee Rs Th2,877.71,731.4 166.2%   
Avg. net profit/employee Rs Th1,879.9280.1 671.3%   
INCOME DATA
Net Sales Rs m132,15328,394 465.4%  
Other income Rs m3,128941 332.6%   
Total revenues Rs m135,28129,334 461.2%   
Gross profit Rs m66,2903,965 1,671.7%  
Depreciation Rs m5,2021,540 337.7%   
Interest Rs m44,0971,962 2,247.1%   
Profit before tax Rs m20,1191,403 1,433.8%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m8,61197 8,850.3%   
Profit after tax Rs m14,701702 2,093.9%  
Gross profit margin %50.214.0 359.2%  
Effective tax rate %42.86.9 617.3%   
Net profit margin %11.12.5 449.9%  
BALANCE SHEET DATA
Current assets Rs m122,74224,836 494.2%   
Current liabilities Rs m310,81018,993 1,636.4%   
Net working cap to sales %-142.320.6 -691.6%  
Current ratio x0.41.3 30.2%  
Inventory Days Days2371 32.5%  
Debtors Days Days39113 34.2%  
Net fixed assets Rs m116,90434,289 340.9%   
Share capital Rs m369895 41.2%   
"Free" reserves Rs m272,16123,651 1,150.8%   
Net worth Rs m272,53024,546 1,110.3%   
Long term debt Rs m270,19615,513 1,741.7%   
Total assets Rs m856,26165,437 1,308.5%  
Interest coverage x1.51.7 84.9%   
Debt to equity ratio x1.00.6 156.9%  
Sales to assets ratio x0.20.4 35.6%   
Return on assets %6.94.1 168.6%  
Return on equity %5.42.9 188.6%  
Return on capital %12.46.9 180.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20015,697 96.8%   
Fx outflow Rs m4,889735 664.8%   
Net fx Rs m10,31214,962 68.9%   
CASH FLOW
From Operations Rs m-115,9751,871 -6,199.5%  
From Investments Rs m-8,2655,826 -141.9%  
From Financial Activity Rs m107,525-10,157 -1,058.6%  
Net Cashflow Rs m-16,650-2,615 636.7%  

Share Holding

Indian Promoters % 52.9 27.7 191.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 37.8 10.6%  
FIIs % 26.6 8.6 309.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 25.9 63.7%  
Shareholders   93,274 56,241 165.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  TTK HEALTHCARE  TORRENT PHARMA  DISHMAN PHARMA  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Kotak Mahindra Bank Jumps 6%(09:30 am)

Asian stock markets are lower today as soaring global coronavirus cases and slow progress on a US stimulus deal dampened investor sentiment.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

My View on ITC(Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

Why ITC and not HUL is my Idea of a Good Investment Right Now(Views On News)

Oct 15, 2020

Rahul Shah discusses HUL's lost decade and its implications for ITC.

Why India's Drone Revolution is a 4x Profit Opportunity(Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.

The Biggest Wealth Creating Opportunity that No One is Talking About(Profit Hunter)

Oct 14, 2020

The defence sector has gone under the radar despite positive developments. Here's why this sector can't be ignored for long...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Oct 27, 2020 12:04 PM

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS